Taiyen Biotech (Taiwan) Insiders
| 1737 Stock | TWD 32.10 0.10 0.31% |
Taiyen Biotech employs about 33 people. The company is managed by 6 executives with a total tenure of roughly 77 years, averaging almost 12.0 years of service per executive, having 5.5 employees per reported executive. Recap of Taiyen Biotech's management performance can provide insight into the venture performance.
| Wei Su Insider Director Department |
| MeiYu Chuang Insider Chief Auditor |
Taiyen |
Taiyen Biotech Management Team Effectiveness
The company has return on total asset (ROA) of 0.0346 % which means that it generated a profit of $0.0346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0642 %, meaning that it generated $0.0642 on every $100 dollars invested by stockholders. Taiyen Biotech's management efficiency ratios could be used to measure how well Taiyen Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Taiyen Biotech Workforce Comparison
Taiyen Biotech Co is number one stock in number of employees category among its peers. The total workforce of Consumer Staples industry is presently estimated at about 12,981. Taiyen Biotech adds roughly 33.0 in number of employees claiming only tiny portion of stocks in Consumer Staples industry.
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12. Taiyen Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Taiyen Biotech Price Series Summation is a cross summation of Taiyen Biotech price series and its benchmark/peer.
Taiyen Biotech Notable Stakeholders
A Taiyen Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Taiyen Biotech often face trade-offs trying to please all of them. Taiyen Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Taiyen Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Wei Su | Director Department | Profile | |
| MeiYu Chuang | Chief Auditor | Profile | |
| MeiWen Chen | Director Department | Profile | |
| TungHsuan Yang | Director Office | Profile | |
| ShiHui Chen | President | Profile | |
| ChiehHan Lee | VP Department | Profile |
About Taiyen Biotech Management Performance
The success or failure of an entity such as Taiyen Biotech often depends on how effective the management is. Taiyen Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Taiyen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Taiyen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Taiyen Biotech Co., Ltd. provides various health and beauty products under the TAIYEN brand Hong Kong, Taiwan, Mainland China, and Macau. The company was founded in 1952 and is based in Tainan, Taiwan. TAIYEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.
Please note, the imprecision that can be found in Taiyen Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Taiyen Biotech Co. Check Taiyen Biotech's Beneish M Score to see the likelihood of Taiyen Biotech's management manipulating its earnings.
Taiyen Biotech Workforce Analysis
Traditionally, organizations such as Taiyen Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Taiyen Biotech within its industry.Taiyen Biotech Manpower Efficiency
Return on Taiyen Biotech Manpower
| Revenue Per Employee | 124.1M | |
| Revenue Per Executive | 682.6M | |
| Net Income Per Employee | 11.9M | |
| Net Income Per Executive | 65.5M | |
| Working Capital Per Employee | 62.9M | |
| Working Capital Per Executive | 345.8M |
Additional Tools for Taiyen Stock Analysis
When running Taiyen Biotech's price analysis, check to measure Taiyen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taiyen Biotech is operating at the current time. Most of Taiyen Biotech's value examination focuses on studying past and present price action to predict the probability of Taiyen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taiyen Biotech's price. Additionally, you may evaluate how the addition of Taiyen Biotech to your portfolios can decrease your overall portfolio volatility.